MX2013005564A - Medicamentos de canabinoides en bajas dosis. - Google Patents

Medicamentos de canabinoides en bajas dosis.

Info

Publication number
MX2013005564A
MX2013005564A MX2013005564A MX2013005564A MX2013005564A MX 2013005564 A MX2013005564 A MX 2013005564A MX 2013005564 A MX2013005564 A MX 2013005564A MX 2013005564 A MX2013005564 A MX 2013005564A MX 2013005564 A MX2013005564 A MX 2013005564A
Authority
MX
Mexico
Prior art keywords
cannabinoid
medicaments
low dose
present
provides methods
Prior art date
Application number
MX2013005564A
Other languages
English (en)
Inventor
Peter Letendre
David Carley
Original Assignee
Pier Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pier Pharmaceuticals filed Critical Pier Pharmaceuticals
Publication of MX2013005564A publication Critical patent/MX2013005564A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar desórdenes sensibles a cannabinoide con un cannabinoide oral de baja dosis que resulta en suministro de un nivel terapéutico durante una ventana terapéutica clínicamente relevante extendida. Estos métodos proporcionan dosis terapéuticas mientras que mantienen niveles seguros y escasos efectos secundarios de un cannabinoide. La presente invención también proporciona métodos para determinar dosis óptima en los pacientes tratados.
MX2013005564A 2010-11-18 2011-11-18 Medicamentos de canabinoides en bajas dosis. MX2013005564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41533110P 2010-11-18 2010-11-18
PCT/US2011/061490 WO2012068516A2 (en) 2010-11-18 2011-11-18 Low dose cannabinoid medicaments

Publications (1)

Publication Number Publication Date
MX2013005564A true MX2013005564A (es) 2014-03-12

Family

ID=46084682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005564A MX2013005564A (es) 2010-11-18 2011-11-18 Medicamentos de canabinoides en bajas dosis.

Country Status (6)

Country Link
US (1) US20130281523A1 (es)
EP (1) EP2640379A4 (es)
AU (1) AU2011329623A1 (es)
BR (1) BR112013012468A2 (es)
MX (1) MX2013005564A (es)
WO (1) WO2012068516A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077572A1 (en) 2013-11-22 2015-05-28 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
US20160015069A1 (en) * 2014-07-15 2016-01-21 Pavel KLEIN Ketogenic food compositions, methods, and uses thereof
GB2531280A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2016071819A1 (en) 2014-11-03 2016-05-12 Ramot At Tel Aviv University Ltd. Methods for treatment of cognitive decline
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US20190125779A1 (en) * 2014-12-30 2019-05-02 University Of Houston System Pharmaceutical compositions
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN107621500A (zh) * 2016-07-14 2018-01-23 上海可力梅塔生物医药科技有限公司 氨基酸与肉碱串联质谱衍生化检测法
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2019135225A1 (en) * 2018-01-03 2019-07-11 Icdpharma Ltd. Solid self-emuslifying cannabinoid compositions
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
US10987391B2 (en) * 2018-08-02 2021-04-27 Slate Podaima Method of agglomerating cannabis extract with energizing consumables
US10813889B2 (en) * 2018-09-04 2020-10-27 Babak Ghalili Cannabinoid and menthol compositions and methods
US11147775B2 (en) 2018-09-04 2021-10-19 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
US10751299B2 (en) * 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10966924B2 (en) 2018-09-04 2021-04-06 Babak Ghalili Veterinary cannabinoid, menthol and anesthetic compositions and methods
US10912806B2 (en) 2018-09-26 2021-02-09 Michael MCGOWAN Composition comprising an essential oil and its packaging thereof
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020234675A1 (en) * 2019-04-30 2020-11-26 Vialpando, Llc Amorphous cannabinoid composition and processes of manufacture
US11596606B2 (en) 2019-05-30 2023-03-07 Metta Medical Inc Activated cannabinoid controlled release compound tablet and method of forming the same
CA3153099A1 (en) * 2019-09-17 2021-03-25 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
GB2608314A (en) 2020-02-11 2022-12-28 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和***

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189491A (en) * 1976-12-16 1980-02-19 Cuendet Jean Francois Tetrahydrocannabinol in a method of treating glaucoma
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
DE60234246D1 (de) * 2001-04-06 2009-12-17 Univ Illinois Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
US20090306037A1 (en) * 2005-05-02 2009-12-10 Merck & Co., Inc. Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity
US20060258738A1 (en) * 2005-05-12 2006-11-16 Douglas Dieterich Use of dronabinol for treatment of side effects of Hepatitis C therapy
US20080181942A1 (en) * 2006-11-30 2008-07-31 University Of Plymouth Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis
EP2184983A1 (en) * 2007-08-06 2010-05-19 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments

Also Published As

Publication number Publication date
EP2640379A4 (en) 2014-08-13
WO2012068516A3 (en) 2012-07-12
WO2012068516A2 (en) 2012-05-24
US20130281523A1 (en) 2013-10-24
BR112013012468A2 (pt) 2016-09-06
AU2011329623A1 (en) 2013-07-11
EP2640379A2 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
MX2013005564A (es) Medicamentos de canabinoides en bajas dosis.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
WO2011063164A3 (en) Sustained release cannabinoid medicaments
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
AU2011328009A8 (en) Compounds and methods for treating pain
WO2012109022A3 (en) Medical fluid delivery device programming
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
EP3517115A3 (en) Methods for treating hyperbilirubinemia with stannsoporfin
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
WO2011163231A3 (en) Combination therapy for the treatment of diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal